Activity Overview
In this online, on-demand educational video, Gus Alva, MD, DFAPA; and Erin Crown, MHS, PA-C will discuss the utility of oral antipsychotics for the treatment of newly diagnosed and previously treated patients with schizophrenia. The expert faculty will review the importance of shared decision-making, treatment adherence, and treatment switching therapies. Case studies will be reviewed to help illustrate how oral antipsychotics can be incorporated into daily practice.
Target Audience
This educational activity is directed toward psychiatrists, nurse practitioners, physician assistants, and nurses who specialize in treating patients with schizophrenia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate clinical trial data for new and emerging agents for schizophrenia
- Incorporate approved agents into management plans for patients with schizophrenia
- Design individualized treatment plans for patients with schizophrenia using shared decision-making principles
Gus Alva, MD, DFAPA
Assistant Professor
Department of Psychiatry and Neuroscience
University of California Riverside
Riverside, CA
Medical Director
ATP Clinical Research
Medical Director, Senior Brain Health
Hoag Hospital
Newport Beach, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Accera, Axovant, Axsome, Biogen, Eisai, Eli Lilly, Genentech, Intra-Cellular Therapies, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Sage, Suven, TransTech; Grant/Research Funding (to institution): AbbVie, Accera, Axovant, Axsome, Biogen, Eisai, Eli Lilly, Genentech, Intra-Cellular Therapies, Janssen, Lundbeck, Neurim, Neurotrope, Novartis, Otsuka, Roche, Sage, Suven, TransTech
Erin Crown, MHS, PA-C
Managing Member
Oasis LifeCare, LLC
Owner
Future Options Research
State College, PA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie,
Bristol Myers Squibb, Intra-Cellular Therapies, Johnson & Johnson,
Lundbeck, Neurocrine Biosciences, Otsuka America Pharmaceutical
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
